GenVec Inc. (GNVC) Expands Contract Supporting Malaria Vaccine Program
7/27/2009 9:26:07 AM
GAITHERSBURG, Md., July 27 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (Nasdaq: GNVC - News) announced the expansion of an existing contract with the PATH Malaria Vaccine Initiative (MVI) to support the development of vaccines to fight malaria through MVI and USAID funding. This contract, valued at approximately $2 million, will continue a collaboration that began in 2004 and will initially support preclinical feasibility studies of novel adenovirus-based vaccines. Based on the results of the feasibility studies, GenVec, MVI, and USAID will contemplate preclinical and clinical development of these vaccines.
comments powered by